including the US Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the NIH. "Obesity drugs won’t be covered by Medicare under 2026 CMS policy" was ...

In his first major action on health care costs this term, President Donald Trump issued a multi-part executive order on ...

The U.S. Food and Drug Administration said Tuesday it will expand its use of unannounced inspections at foreign manufacturing ...

Small molecule drugs are eligible for selection to the drug price negotiation program seven years after Food and Drug Administration ... result in more savings for Medicare beneficiaries.

The Centers for Medicare and Medicaid Services recently announced ... The drugs have already received additional indications from the U.S. Food and Drug Administration to lower the risk of heart ...

Both Original Medicare (Part A and Part B) and Medicare Advantage (Part C) provide coverage for: Medicare Part D covers various diabetic supplies, insulin, and antidiabetic drugs. One of the ...

President Trump issued an Executive Order instructing federal agencies to implement a variety of drug pricing reforms.

For a drug to receive Medicare coverage, it must have Food and Drug Administration (FDA) approval, and a Part D plan’s formulary must include the drug. A formulary is a list of covered medications.

The Biden administration proposal on obesity drugs In November 2024, The Biden administration proposed a rule that would allow both Medicare and Medicaid to cover weight loss drugs beginning in 2026.

The Centers for Medicare and Medicaid Services ... not proceed with a proposal initiated by the Biden Administration to cover weight-loss drugs like Wegovy and Zepbound for its beneficiaries.